Stocks · Healthcare · Biotechnology
MediciNova, Inc. MNOV
$1.76 -1.12% Close, Oct 5, 2026 · NASDAQ · Market cap $87.6M
Expensive vs sector
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $920,481, up 583.9% from a year earlier.
- Operating margin widened to -1287.4% from -9883.0% a year earlier.
- The stock is in an uptrend: above its 200-day average for 26 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 4%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 40%
- Gross marginBottom 27%
- Operating marginBottom 10%
- Accruals (lower is better)Bottom 1%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 41%
- Free-cash-flow yieldBottom 1%
- EBITDA / enterprise valueBottom 30%
- Sales / enterprise valueBottom 11%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 43%
- 6-month returnTop 37%
- 1-year return vs S&P 500Top 30%
- Distance from 52-week highBottom 22%
- Trend checklist (0–4)Top 26%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 20%
- Consecutive EPS beatsTop 19%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 15%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 6%
- Maximum drawdown, 3 yearsTop 26%
- Beta vs S&P 500 (lower is better)Top 18%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Gross margin | 9.7% | 42.4% | ↑ |
| Operating margin | -9883.0% | -1287.4% | ↑ |
| FCF margin | -7469.5% | -209374.2% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 583.9% | — | Top 4% | |
| Gross margin | 42.4% | 9.7% | ↑ | Bottom 27% |
| Operating margin | -1287.4% | -9883.0% | ↑ | Bottom 10% |
| Net margin | -1168.2% | -8775.8% | ↑ | — |
| Free-cash-flow margin | -209374.2% | -7469.5% | ↓ | — |
| Return on invested capital | -31.5% | — | Bottom 40% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 4739.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 19284.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -683.9 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.00%
- Shareholder yield
- 0.00%
- Share count change, 1 year
- +0.4%
- Share count change, 3-year CAGR
- +0.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 4
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +24.9%
- Average 2-day reaction, last 8
- -2.2%
- Positive 20 days after report
- 2 of 8
Analysts
- Consensus price target
- $6.00
- Target vs current price
- +240.9%
- Analysts with a rating
- 4
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | +21.0% | -1.5% | +3.8% | +30.8% | — |
| May 15, 2026 | +16.7% | -1.4% | -2.1% | -12.1% | -5.7% |
| Feb 20, 2026 | +36.8% | -3.2% | -1.9% | -10.3% | -11.0% |
| Nov 13, 2025 | +25.0% | -1.9% | -8.9% | -3.8% | +3.8% |
| Aug 14, 2025 | +0.0% | +2.4% | +3.1% | -1.6% | +10.2% |
| May 14, 2025 | +57.1% | -6.2% | -6.2% | -6.8% | -7.5% |
| Feb 19, 2025 | +0.0% | +2.6% | -9.4% | -21.9% | -28.6% |
| Nov 14, 2024 | +0.0% | -8.5% | -2.5% | +7.0% | -8.0% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.05 | -$0.06 | +21.0% | $459,000 |
| May 15, 2026 | -$0.05 | -$0.06 | +16.7% | $186,984 |
| Feb 20, 2026 | -$0.06 | -$0.10 | +36.8% | $151,000 |
| Nov 13, 2025 | -$0.06 | -$0.08 | +25.0% | $61,500 |
| Aug 14, 2025 | -$0.07 | -$0.07 | +0.0% | $134,599 |
| May 14, 2025 | -$0.06 | -$0.14 | +57.1% | — |
| Feb 19, 2025 | -$0.06 | -$0.06 | +0.0% | — |
| Nov 14, 2024 | -$0.06 | -$0.06 | +0.0% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 67.70× | — | — | Bottom 11% |
| Free-cash-flow yield | -2199.71% | — | — | Bottom 1% |
| Earnings yield | -12.34% | — | — | Bottom 41% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 2
- Days above the 200-day average
- 26
- 50-day average slope (20 days)
- +26.1%
- 200-day average slope (20 days)
- +5.5%
- Distance from 50-day average
- +1.1%
- Distance from 200-day average
- +16.8%
- RSI (14)
- 43.0
- Relative volume
- 0.23×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 113.8%
- Volatility vs own 5-year history
- 98th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.55
- Correlation with S&P 500
- 0.10
- Current drawdown from 1-year high
- -49.0%
- Maximum drawdown, 3 years
- -52.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 10, 2021 | Aug 7, 2024 | -87.1% | 858 days | Not yet recovered |
| Feb 8, 2021 | Mar 4, 2021 | -21.3% | 17 days | 4 days (Mar 10, 2021) |
| Nov 17, 2020 | Dec 28, 2020 | -20.3% | 27 days | 26 days (Feb 4, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $87.6M
- EPS, diluted (TTM)
- -$0.22
- Revenue (TTM)
- $920,481
- 52-week range
- $1.17 – $3.90
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $4.0M | $0 | $1.0M | $0 | $409,657 |
| Gross profit | $4.0M | $0 | $1.0M | $0 | $31,051 |
| Operating income | -$10.2M | -$14.6M | -$9.9M | -$12.7M | -$13.3M |
| Net income | -$10.1M | -$14.1M | -$8.6M | -$11.0M | -$12.0M |
| EPS (diluted) | -$0.21 | -$0.29 | -$0.17 | -$0.23 | -$0.24 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $134,599 | $123,319 | $151,739 | $186,984 | $458,439 |
| Net income | -$2.9M | -$2.8M | -$2.9M | -$3.3M | -$3.1M | -$2.8M | -$2.6M | -$2.3M |
| EPS (diluted) | -$0.06 | -$0.06 | -$0.06 | -$0.07 | -$0.06 | -$0.05 | -$0.05 | -$0.05 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$9.4M | -$12.9M | -$7.4M | -$10.6M | -$9.8M |
| Capital expenditure | -$28,732 | -$5,010 | -$21,299 | -$895 | -$2,899 |
| Free cash flow | -$9.4M | -$12.9M | -$7.5M | -$10.6M | -$9.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $20.9M | $7,920 | $0 | $0 | $0 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $25.4M
- Total assets
- $40.4M
- Total liabilities
- $3.2M
- Total debt
- $117,038
- Net debt
- -$25.3M
- Shareholders’ equity
- $37.3M
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 374,674
- Days to cover
- 4.27
- Change vs previous report
- +1.4%
FINRA short interest, settlement date Sep 15, 2026.